Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2017 / Cilt: 57 - Sayı: 2

What is the Gold Standard in the Differential Diagnosis of Microangiopathic Hemolytic Anemia? Is it ADAMTS13 Activity, Platelet Count, or Serum Creatinine Level?

Mikroanjiyopatik Hemolitik Anemi Ayırıcı Tanısında Altın Standart Nedir? ADAMTS13 Aktivitesi mi, Trombosit Sayısı mı, Serum Kreatinin Düzeyi mi?

Pages
68–72
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mild thrombocytopenia, normal or mild/moderate decrease in ADAMTS13 activity level, and increased serum creatinine level are present in HUS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The aim of this study was to analyze the value of ADAMTS13 measurement and other hemolysis tests in the diagnosis of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
📊
Key Findings & Data:Methods: Data of patients with microangiopathic hemolytic anemia (MAHA) at presentation who were treated at the Eskisehir Osmangazi University Faculty of Medicine Internal Medicine Department from 2014 to 2016 were analyzed retrospectively.
💡
Conclusion & Impact:Mild thrombocytopenia, normal or mild/moderate decrease in ADAMTS13 activity level, and increased serum creatinine level are present in HUS.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: The aim of this study was to analyze the value of ADAMTS13 measurement and other hemolysis tests in the diagnosis of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Methods: Data of patients with microangiopathic hemolytic anemia (MAHA) at presentation who were treated at the Eskisehir Osmangazi University Faculty of Medicine Internal Medicine Department from 2014 to 2016 were analyzed retrospectively. ADAMTS13 activity and other laboratory tests were examined in TTP (n=6), HUS (n=5), and other MAHA (n=8) patients.Results: ADAMTS13 activity and platelet count level were significantly lower in TTP patients compared with the HUS and other MAHA patients groups (p=0.014, p=0.028, respectively). There was a significant correlation between ADAMTS13 activity level, platelet count (p=0.001; r=0.693), and serum creatinine level (p=0.008; r=0.589) in diagnosis. A severely decreased ADAMTS13 activity level was significant in the TTP group compared with the HUS and other MAHA patients groups (p=0.048).Discussion and Conclusion: Severe thrombocytopenia and severe ADAMTS13 activity deficiency upon diagnosis of MAHA is not present in HUS disease, but is present in TTP. Mild thrombocytopenia, normal or mild/moderate decrease in ADAMTS13 activity level, and increased serum creatinine level are present in HUS.

Özet

Giriş ve Amaç: Çalışmamızın amacı, trombotik trombositopenik purpura (TTP) ve hemolitik üremik sendromun (HÜS) tanısı sırasında, ADAMTS13 düzeylerini ve diğer hemoliz parametrelerini değerlendirmek ve sonuçlarla ayırıcı tanıya varabilmektedir.Yöntem ve Gereçler: 2014-2016 yılları arasında Eskişehir Osmangazi Üniversitesi Tıp Fakültesi İç Hastalıkları Kliniğinde mikroanjiyopatik hemolitik anemi (MAHA) kliniği ile başvuran ve tedavileri yapılan hastalar retrospektif olarak değerlendirildi. ADAMTS13 aktivitesi ve diğer laboratuvar testleri TTP (n=6), HÜS (n=5) ve diğer MAHA'li (n=8) hastalarda çalışıldı. Bulgular: HÜS ve diğer MAHA grupları ile karşılaştırıldığında TTP hastalarında, hem ADAMTS13 aktivitesi hem de trombosit sayıları istatistiksel açıdan anlamlı derecede düşük saptandı (p=0.014, p=0.028). ADAMTS13 aktivitesi ile tanı öncesi trombosit sayısı (p=0.001, r=0.693) ve serum kreatinin (p=0.008, r=0.589) düzeyleri arasında pozitif korelasyon saptandı. ADAMTS13 aktivitesi TTP grubunda en düşük düzeylerde, HÜS ve diğer grubunda ise orta-yüksek düzeylerde saptandı (p=0.048).Tartışma ve Sonuç: MAHA tanısı sırasında ciddi trombositopeni ve çok düşük ADAMTS13 aktivite düzeylerinin varlığı HÜS tanısı için bir bulgu değilken, TTP tanısını işaret etmektedir. Ilımlı bir trombositopeni, normal veya hafif/orta düzeyde azalmış ADAMTS13 aktivite düzeyleri ve artmış serum kreatinin düzeylerinin varlığı ise HÜS tanısını desteklemektedir.

🔖

Cite This Article

EMİR, B., TEKE, H. Ü., GÜNDÜZ, E., CANSU, D. Ü., AKYOL, G., AKAY, O. M., ANDİÇ, N., BOZACİ, İ. (2022). What is the Gold Standard in the Differential Diagnosis of Microangiopathic Hemolytic Anemia? Is it ADAMTS13 Activity, Platelet Count, or Serum Creatinine Level?. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 57 - Sayı: 2, 68–72. https://ajindex.com/articles/535237

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica 2007;92:878-80
  2. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98:1765-72
  3. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-8
  4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94
  5. Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol 2001;112:1087-8
  6. Vucelic D, Mikovic D, Rajic Z, Savic N, Budisin Z, Antonijevic NM, et al. Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. Srp Arh Celok Lek 2013;141:466-74
  7. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9
  8. Myers L. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: pathophysiology and management. Nephrol Nurs J 2002;29:171-80
  9. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004;127:433-9.